GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJY) » Definitions » Total Receivables

UCB (UCBJY) Total Receivables : $1,474 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is UCB Total Receivables?

UCB's Total Receivables for the quarter that ended in Jun. 2024 was $1,474 Mil.


UCB Total Receivables Historical Data

The historical data trend for UCB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Total Receivables Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 867.78 1,037.71 1,176.27 931.14 1,129.77

UCB Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,399.58 931.14 1,288.19 1,129.77 1,473.63

UCB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


UCB Total Receivables Related Terms

Thank you for viewing the detailed overview of UCB's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB Business Description

Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).